Ajai Chari (A Chari)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 38

Top Topics

Multiple Myeloma

Acute Lymphoblastic Leukemia

Top Venues

Leukemia & lymphoma

Blood cancer journal

Expert review of hematology

Blood cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Ajai Chari, Jonathan L Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi N Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano José Megale Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A Holstein, Caitlin Costello, Andrzej J Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul Gerard Richardson
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood cancer journal 14 (1) (2024)
Anup Joseph Devasia, Ajai Chari, Guido Lancman
Bispecific antibodies in the treatment of multiple myeloma. Blood cancer journal 14 (1) (2024)
Santiago Thibaud, Ryan L Subaran, Scott Newman, Alessandro Lagana, David T Melnekoff, Saoirse Bodnar, Meghana Ram, Zachry Soens, William Genthe, Tehilla E Brander, Tarek H Mouhieddine, Oliver Van Oekelen, Jane Houldsworth, Hearn Jay Cho, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa J Sanchez, Ajai Chari, Erin Laverne Moshier, Sundar Jagannath, Samir S Parekh, Kenan Onel
Multiple Myeloma Risk and Outcomes are Associated with Pathogenic Germline Variants in DNA Repair Genes. Blood cancer discovery (2024)
Joaquin Martinez Lopez, Nieves López-Muñoz, Ajai Chari, Sara Dorado, S Barrio, S Arora, A Kumar, A Chung, Thomas G Martin, J Wolf
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood cancer journal 14 (1) (2024)
Joaquin Martinez Lopez, Nieves López-Muñoz, Ajai Chari, Sara Dorado, S Barrio, S Arora, A Kumar, A Chung, Thomas G Martin, J Wolf
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood cancer journal 14 (1) (2024)
Ajai Chari, Jonathan L Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi N Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano José Megale Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A Holstein, Caitlin Costello, Andrzej J Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul Gerard Richardson
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood cancer journal 14 (1) (2024)
Sheri Skerget, Daniel Penaherrera, Ajai Chari, Sundar Jagannath, David S Siegel, Ravi Vij, Gregory Orloff, Andrzej Jakubowiak, Ruben Niesvizky, Darla K Liles, Jesus G Berdeja, Moshe Levy, Jeffrey Wolf, Saad Z Usmani, null null, Austin W Christofferson, Sara Nasser, Jessica L Aldrich, Christophe Legendre, Brooks A Benard, Chase Miller, Bryce Turner, Ahmet Kurdoglu, Megan Washington, Venkata D Yellapantula, Jonathan R Adkins, Lori Cuyugan, Martin Boateng, Adrienne Helland, Shari Kyman, Jackie McDonald, Rebecca Reiman, Kristi Stephenson, Erica Tassone, Alex Blanski, Brianne Livermore, Meghan Kirchhoff, Daniel C Rohrer, Mattia D'Agostino, Manuela Gamella, Kimberly Collison, Jennifer Stumph, Pam Kidd, Andrea Donnelly, Barbara Zaugg, Maureen Toone, Kyle McBride, Mary DeRome, Jennifer Rogers, David Craig, Winnie S Liang, Norma C Gutiérrez, Scott D Jewell, John Carpten, Kenneth C Anderson, Hearn Jay Cho, Daniel Auclair, Sagar Lonial, Jonathan J Keats
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nature genetics (2024)
Joaquin Martinez Lopez, Nieves López-Muñoz, Ajai Chari, Sara Dorado, S Barrio, S Arora, A Kumar, A Chung, Thomas G Martin, J Wolf
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood cancer journal 14 (1) (2024)
Ajai Chari, Jonathan L Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi N Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano José Megale Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A Holstein, Caitlin Costello, Andrzej J Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul Gerard Richardson
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood cancer journal 14 (1) (2024)
Ajai Chari, Jonathan L Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi N Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano José Megale Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A Holstein, Caitlin Costello, Andrzej J Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul Gerard Richardson
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood cancer journal 14 (1) (2024)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Guido Lancman, Kian Parsa, Krzysztof Kotlarz, Lisa Avery, Alaina Lurie, Alex Lieberman-Cribbin, Hearn Jay Cho, Samir S Parekh, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa J Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood cancer discovery (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma (2023)
Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Z Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N Libby, Maria Chaudhry, Malin Hultcrantz, K Martin Kortüm, Rakesh Popat, Douglas Sborov, Shawn Hakim, Eric Lewis, Boris Gorsh, Bharat Bhushan, Astrid McKeown, Ira Gupta, Joanna Opalinska, Paul G Richardson, Sagar Lonial
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Faith E Davies, Charlotte Pawlyn, Saad Z Usmani, Jesús San F Miguel, Hermann Einsele, Eileen Mary Boyle, Jill Corre, Daniel Auclair, Hearn Jay Cho, Sagar Lonial, Pieter Sonneveld, A Keith Stewart, Peter Leif Bergsagel, Martin F Kaiser, Katja Weisel, Jonathan J Keats, Joseph R Mikhael, Kathryn E Morgan, Irene M Ghobrial, Robert Z Orlowski, Carl Ola Landgren, Francesca Gay, Joseph Caers, Wee-Joo Chng, Ajai Chari, Brian A Walker, Shaji K Kumar, Luciano José Megale Costa, Kenneth C Anderson, Gareth J Morgan
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood cancer discovery 3 (4) (2022)
Paula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, Adolfo Aleman, Violetta V Leshchenko, David T Melnekoff, Sarita Agte, Joy J Jiang, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J Walker, Yosef Landesman, Alessandro Laganà, Samir S Parekh
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO precision oncology 6 (2022)
Sikandar Ailawadhi, Augustina Ogbonnaya, Sharanya Murty, Dasha Cherepanov, Bridgette Kanz Schroader, Dorothy Romanus, Eileen Farrelly, Ajai Chari
Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant. Cancer medicine (2022)
Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Chari
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Therapeutic advances in hematology 12 (2021)
Xavier Leleu, Ajai Chari, Shambavi Richard, Monica Khurana, Akeem Yusuf, Saad Z Usmani
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. Expert review of hematology (2021)
Guido Lancman, Dahniel L Sastow, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir S Parekh, Shambavi Richard, Joshua Richter, Larysa Sanchez, Ajai Chari
Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood cancer discovery 2 (5) (2021)
Sagar Lonial, Hans C Lee, Ashraf Z Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Douglas Sborov, Attaya Suvannasankha, Katja Weisel, Peter M Voorhees, Lynsey Womersley, January Baron, Trisha Piontek, Eric Lewis, Joanna Opalinska, Ira Gupta, Adam D Cohen
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 127 (22) (2021)
Clifton C Mo, Sundar Jagannath, Ajai Chari, Ajay K Nooka, Sagar Lonial, David Siegel, Noa Biran, Cristina Gasparetto, Nizar J Bahlis, Paul Richardson
Selinexor for the treatment of patients with previously treated multiple myeloma. Expert review of hematology 14 (8) (2021)
Darren Pan, Jonathan L Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder, Robert F Cornell, Jeffrey A Zonder, Joseph W Fay, Manuel R Modiano, Erin L Moshier, Selena A Rush, Brian J Tunquist, Ajai Chari
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer medicine 11 (2) (2021)
Thomas G Martin, Nina Shah, Joshua Richter, David H Vesole, Sandy W Wong, Chiung-Yu Huang, Deepu Madduri, Sundar Jagannath, David S Siegel, Noa Biran, Jeffrey L Wolf, Samir Parekh, Hearn J Cho, Pamela Munster, Shambavi Richard, Samira Ziti-Ljajic, Ajai Chari
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer 127 (11) (2021)
Paul Gerard Richardson, Sundar Jagannath, Ajai Chari, Dan T Vogl, Meletios A Dimopoulos, Philippe Moreau, David Dingli, Lee-Jen Wei, Joshua Richter, Noa Biran, David Siegel, William Reichmann, Lingling Li, Shijie Tang, Jean-Richard Saint-Martin, Anita Joshi, Michael Kauffman, Jatin Shah, Sharon Shacham, Sagar Lonial
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. EJHaem 2 (1) (2020)
Ajai Chari, Paul G Richardson, Dorothy Romanus, Meletios- Athanasios Dimopoulos, Pieter Sonneveld, Evangelos Terpos, Roman Hajek, Aditya Raju, Antonio Palumbo, Lauren E Cain, Marlo Blazer, Hui Huang, Eileen Farrelly, Sikander Ailawadhi
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert review of hematology 13 (4) (2020)
Ajai Chari, Paula Rodriguez-Otero, Helen McCarthy, Kenshi Suzuki, Vania Hungria, Anna Sureda, Aurore Perrot, Cyrille Hulin, Hila Magen, Shinsuke Iida, Vladimir Maisnar, Lionel Karlin, Ludek Pour, Dolly A Parasrampuria, Tara Masterson, Michele Kosh, Shiyi Yang, Maria Delioukina, Ming Qi, Robin Carson, Cyrille Touzeau
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. British journal of haematology 192 (5) (2020)
Ajai Chari, Robert F Cornell, Cristina Gasparetto, Chatchada Karanes, Jeffrey V Matous, Ruben Niesvizky, Matthew Lunning, Saad Z Usmani, Larry D Anderson, Saurabh Chhabra, Saulius Girnius, Chaim Shustik, Robert Stuart, Yihua Lee, Zeena Salman, Emily Liu, Jason Valent
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological oncology 38 (3) (2020)
Deepu Madduri, May Hagiwara, Kejal Parikh, Corey Pelletier, Thomas E Delea, Arianna Kee, Ajai Chari
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future oncology (London, England) 17 (5) (2020)
Larysa J Sanchez, Kevin Barley, Joshua Richter, Joseph Franz, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Ajai Chari
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. Expert review of hematology 13 (9) (2020)
Oliver Van Oekelen, Samir Parekh, Hearn J Cho, Nivetha Vishnuvardhan, Deepu Madduri, Joshua Richter, Chun Ip, Kenneth Lau, Erika Florendo, Ines S Mancia, Joanne Thomas, Daniel Verina, Elaine Chan, Katarzyna Zarychta, Lisa La, Gina Strumolo, David T Melnekoff, Violetta V Leshchenko, Seunghee Kim-Schulze, Suzana Couto, Maria Wang, William E Pierceall, Anjan Thakurta, Alessandro Laganà, Sundar Jagannath, Ajai Chari
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia & lymphoma 61 (9) (2020)
Xavier Leleu, Meral Beksac, Takaaki Chou, Meletios- Athanasios Dimopoulos, Sung-Soo Yoon, H Miles Prince, Ludek Pour, Tatiana Shelekhova, Ajai Chari, Monica Khurana, Jianqi Zhang, Mihaela Obreja, Ming Qi, Albert Oriol, David Siegel
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leukemia & lymphoma 62 (2) (2020)
Shambavi Richard, Sundar Jagannath, Hearn Jay Cho, Samir Parekh, Deepu Madduri, Joshua Richter, Ajai Chari
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Expert review of hematology 14 (1) (2020)
Ajai Chari, Bart Barlogie
Imipridone ONC201: combination therapy in hematologic malignancies. Cell cycle (Georgetown, Tex.) 17 (16) (2018)